Vertex Pharmaceuticals announced the first accepted ... Vertex will present data on the vanza triple in an oral presentation and two posters on Friday, September 27. This is the first time that ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq ... and Non-surgical Conditions” will be presented in a poster session on Saturday, October 19, from 10:00-11:30 a.m ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $478.09, reflecting a -1.02% shift from the previouse trading day's closing. This change lagged the S&P 500's 0 ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.26% of ...

Vertex Pharmaceuticals has a virtual monopoly in treating cystic fibrosis, having created and brought to market a function cure for 90% of the CF population. Their pipeline outside of CF has shown ...

Jessica Fye has given her Buy rating due to a combination of factors that highlight Vertex Pharmaceuticals’ promising developments, particularly concerning their drug suzetrigine. The recent ...

In the preceding three months, 19 analysts have released ratings for Vertex Pharmaceuticals VRTX, presenting a wide array of perspectives from bullish to bearish. The table below provides a ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) and keeping the price target at $473.00. Terence Flynn has given his Hold ...

15 analysts have expressed a variety of opinions on Vertex Pharmaceuticals (NASDAQ:VRTX) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides ...